479 Jessie Street
San Francisco, CA 94103
Convalesce’s platform technology addresses the challenges of stem cell transplantation in the CNS. The company’s proprietary extra-cellular matrix (ECM) technology with engineered peptides mimic the natural brain tissue and promotes stem cell survival and neuronal differentiation at the transplant site. Convalesce’s first indication is Parkinson’s disease, using a formulation combining its ECM technology with specific growth factors and ligands to obtain targeted differentiation of stem cells to dopaminergic neurons.